Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 4/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL385702 | 0.98 | NPC1 (0.63) | NPC1MCHR1LTA4HPTGS1PTGS2 | |
| SCHEMBL385701 | 0.98 | NPC1 (0.63) | NPC1MCHR1LTA4HPTGS1PTGS2 | |
| SCHEMBL15009138 | 0.89 | NPC1 (0.47) | NPC1HRH3GNAI3GNAO1GNAI1 | |
| SCHEMBL15009139 | 0.89 | NPC1 (0.47) | NPC1HRH3GNAI3GNAO1GNAI1 | |
| SCHEMBL13939521 | 0.82 | NPC1 (0.88) | NPC1MCHR1LTA4HPSMB1PSMB5 | |
| SCHEMBL16016535 | 0.82 | NPC1 (0.88) | NPC1MCHR1LTA4HPSMB1PSMB5 | |
| SCHEMBL14654909 | 0.81 | NPC1 (0.60) | NPC1MCHR1HRH3TDP1ALDH1A1 | |
| SCHEMBL77295 | 0.77 | NPC1 (0.60) | NPC1MCHR1LTA4HHRH3GNAI3 | |
| SCHEMBL13367 | 0.77 | NPC1 (0.66) | NPC1MCHR1LTA4HPSMB1PSMB5 | |
| SCHEMBL14652221 | 0.77 | NPC1 (0.55) | NPC1MCHR1PSMB1PSMB5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912180-B2 | Heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2014-12-16 | — | — | US | disclosed |
| US-8912180-B2 | Heterocyclic compound | ASTELLAS PHARMA INC. (JP) | 2014-12-16 | — | — | US | disclosed |
| US-20130150364-A1 | HETEROCYCLIC COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150364-A1 | HETEROCYCLIC COMPOUND | IL2, NFATC1, ICOS | NPC1 4398/4885MCHR1 2891/4885LTA4H 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.